D3.152 - The quality of life in severe asthma patients treated with biologics is better than those with triple inhaler therapy

When severe asthma patients are controlled with their treatment, clinicians typically don’t modify their medication. This study aims to compare the quality of life between controlled severe asthma patients receiving triple inhaler therapy and those treated with biologics.

A single tertiary centre study was designed as a cross-sectional and real-life study.  Controlled severe asthma patients (Asthma Control Test ≥ 20) receiving triple therapy (ICS/LABA/LAMA) or biologics completed the Severe Asthma Questionnaire (SAQ). Results were compared according to treatment with or without biologics.

The triple-therapy group included 40 women and 6 men (mean age: 51.1±12), whereas the biologics group included 20 women and 7 men (mean age: 52.5±13.4). The duration of asthma was longer in the biologic group than the triple-therapy group (26.9±5.1 vs 14.8±11.2, p<0.001). The smoking history, body mass index, allergic status, number of comorbidities and spirometric parameters did not differ between groups (p>0.05).  The total SAQ scores were higher in the biologics group compared with the triple-therapy group (p<0.05) (Table 1). 

The quality of life in controlled severe asthma patients treated with biologics was better than those with triple-therapy alone